ARTICLE | Company News

Pfizer sales and marketing update

August 22, 2016 7:00 AM UTC

The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Xalkori crizotinib from Pfizer for untreated, anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) -- its approved indication. NICE’s decision reverses draft guidance it issued in May, when the agency recommended against the drug’s use on the grounds that it was not cost-effective compared with standard of care chemotherapy, even at a discount offered by Pfizer. NICE’s new recommendation is contingent on the pharma providing Xalkori at a larger discount under a patient access scheme. ...